ALX Oncology Holdings Inc (ALXO)
1.29
-0.04
(-3.01%)
USD |
NASDAQ |
Nov 15, 16:00
1.29
0.00 (0.00%)
After-Hours: 20:00
ALX Oncology Holdings Cash and Short Term Investments (Quarterly): 148.57M for Sept. 30, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 148.57M |
| June 30, 2024 | 156.72M |
| March 31, 2024 | 157.44M |
| December 31, 2023 | 182.74M |
| September 30, 2023 | 190.01M |
| June 30, 2023 | 212.84M |
| March 31, 2023 | 227.94M |
| December 31, 2022 | 266.21M |
| September 30, 2022 | 284.91M |
| June 30, 2022 | 313.37M |
| Date | Value |
|---|---|
| March 31, 2022 | 316.60M |
| December 31, 2021 | 363.67M |
| September 30, 2021 | 385.15M |
| June 30, 2021 | 409.96M |
| March 31, 2021 | 429.86M |
| December 31, 2020 | 434.22M |
| September 30, 2020 | 259.48M |
| June 30, 2020 | 98.10M |
| March 31, 2020 | 105.04M |
| December 31, 2019 | 9.017M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
9.017M
Minimum
Dec 2019
434.22M
Maximum
Dec 2020
247.59M
Average
243.71M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 930.44M |
| Neurocrine Biosciences Inc | 1.228B |
| Eton Pharmaceuticals Inc | 17.69M |
| Verve Therapeutics Inc | 539.92M |
| Immuneering Corp | 59.73M |